Oncoinvent AS: Data From the Ongoing Radspherin RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients to Be Presented at the 2022 ASCO Annual Meeting

All dose levels of Radspherin were well tolerated with a maximum dose level toxicity not reached in the RAD-18-002 study. Radspherin is currently being evaluated in two ongoing Phase 1 trials for

Related Keywords

Norway ,United States ,Chicago ,Illinois ,American ,Norwegian ,Jana Alfheim ,Courtney Turiano ,Steing Larsen ,Kostenloser Wertpapierhandel ,Stein Gunnar Larsen ,American Society Of Clinical Oncology ,Linear Energy Transfer ,Uppsala University Hospital ,Clinical Oncology ,Annual Meeting ,Principle Investigator Stein Gunnar Larsen ,Cancer Colorectal ,Chief Executive Officer ,Presentation Title ,Gastrointestinal Cancer Colorectal ,Norwegian Radium Hospital ,Stern Investor Relations ,Oncoinvent ,Data ,Rom ,Ngoing ,Adspherin ,Hase ,Trial ,Olorectal ,Dancer ,Patients ,Resented ,022 ,Disco ,Nnual ,Meeting ,